These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1049 related articles for article (PubMed ID: 11395636)
1. Identification of a New Shared HLA-A2.1 Restricted Epitope From the Melanoma Antigen Tyrosinase. Riley JP; Rosenberg SA; Parkhurst MR J Immunother (1991); 2001 May; 24(3):212-220. PubMed ID: 11395636 [TBL] [Abstract][Full Text] [Related]
2. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. Riley JP; Rosenberg SA; Parkhurst MR J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498 [TBL] [Abstract][Full Text] [Related]
3. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Salazar-Onfray F; Nakazawa T; Chhajlani V; Petersson M; Kärre K; Masucci G; Celis E; Sette A; Southwood S; Appella E; Kiessling R Cancer Res; 1997 Oct; 57(19):4348-55. PubMed ID: 9331097 [TBL] [Abstract][Full Text] [Related]
4. Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Parkhurst MR; Fitzgerald EB; Southwood S; Sette A; Rosenberg SA; Kawakami Y Cancer Res; 1998 Nov; 58(21):4895-901. PubMed ID: 9809996 [TBL] [Abstract][Full Text] [Related]
5. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560 [TBL] [Abstract][Full Text] [Related]
6. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P; Micheli L; Vecchio MT; Sabatino M; Petrioli R; Pozzessere D; Marsili S; Giorgi G; Lozzi L; Neri P; Francini G Br J Cancer; 2001 Nov; 85(11):1722-30. PubMed ID: 11742494 [TBL] [Abstract][Full Text] [Related]
7. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913 [TBL] [Abstract][Full Text] [Related]
8. Mammaglobin-A is a tumor-associated antigen in human breast carcinoma. Tanaka Y; Amos KD; Fleming TP; Eberlein TJ; Goedegebuure PS Surgery; 2003 Jan; 133(1):74-80. PubMed ID: 12563241 [TBL] [Abstract][Full Text] [Related]
9. Allo-restricted CTLs generated by coculturing of PBLs and autologous monocytes loaded with allogeneic peptide/HLA/IgG1-Fc fusion protein. Weng X; Lu S; Zhong M; Liang Z; Shen G; Chen J; Wu X J Leukoc Biol; 2009 Mar; 85(3):574-81. PubMed ID: 19112092 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047 [TBL] [Abstract][Full Text] [Related]
11. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients. Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794 [TBL] [Abstract][Full Text] [Related]
12. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24. Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648 [TBL] [Abstract][Full Text] [Related]
13. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401 [TBL] [Abstract][Full Text] [Related]
14. Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients. Jaramillo A; Narayanan K; Campbell LG; Benshoff ND; Lybarger L; Hansen TH; Fleming TP; Dietz JR; Mohanakumar T Breast Cancer Res Treat; 2004 Nov; 88(1):29-41. PubMed ID: 15538043 [TBL] [Abstract][Full Text] [Related]
15. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Sensi M; Pietra G; Molla A; Nicolini G; Vegetti C; Bersani I; Millo E; Weiss E; Moretta L; Mingari MC; Anichini A Int Immunol; 2009 Mar; 21(3):257-68. PubMed ID: 19181932 [TBL] [Abstract][Full Text] [Related]
16. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients. Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401 [TBL] [Abstract][Full Text] [Related]
17. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421 [TBL] [Abstract][Full Text] [Related]
18. [Prediction synthesis and identification of HLA-A2-restricted cytotoxic T lymphocyte epitopes of the tumor antigen MAGE-n]. Dong HL; Sui YF; Ye J; Li ZS; Qu P; Zhang XM; Chen GS; Lu SY Zhonghua Yi Xue Za Zhi; 2003 Jun; 83(12):1080-3. PubMed ID: 12899783 [TBL] [Abstract][Full Text] [Related]
19. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Lapointe R; Bellemare-Pelletier A; Housseau F; Thibodeau J; Hwu P Cancer Res; 2003 Jun; 63(11):2836-43. PubMed ID: 12782589 [TBL] [Abstract][Full Text] [Related]
20. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Di Nicola M; Carlo-Stella C; Mortarini R; Baldassari P; Guidetti A; Gallino GF; Del Vecchio M; Ravagnani F; Magni M; Chaplin P; Cascinelli N; Parmiani G; Gianni AM; Anichini A Clin Cancer Res; 2004 Aug; 10(16):5381-90. PubMed ID: 15328176 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]